Danish drugmaker Novo Nordisk on Friday introduced Ozempic, its once-weekly semaglutide injection for type-2 diabetes, into the Indian market, marking one of the most anticipated diabetes-and-weight-management launches in recent years. The therapy, already widely prescribed globally, will be available at ₹8,800 for 0.25 mg, ₹10,170 for 0.5 mg and ₹11,175 for 1 mg, translating to a weekly starting dose of roughly ₹2,200. Advertisement

The launch comes at a critical time for India, which now has 101 million people living with diabetes, according to WHO’s 2023–24 estimates, the second-highest number in the world after China. Another 136 million Indians have prediabetes, while 254 million live with generalised obesity, deepening concerns around metabolic disease and associated complications.

See Full Page